Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Scope of Study
3.2 Research Objective
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Primary Research Methodology
4.2 Data points received from the Specialist Doctors:
4.3 Data points received from the Manufacturer/ Pharmaceutical Companies:
4.4 Data points received from Hospitals, Diagnostic Centers:
4.5 Secondary Research Methodology
4.6 Market Share Analysis
4.7 Trade Analysis
4.8 Market Pricing Approach
4.9 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Growing number of stem cell, soft-tissue, and solid organ, transplantation procedures
5.2.2 Rising occurrence of chronic and infectious diseases
5.2.3 Increasing Awareness Related to Transplant Diagnostic Procedures
5.3 Restraints
5.3.1 Shortage of donor organ and limited medical reimbursement
5.3.2 High cost of NGS- and PCR-based devices
5.4 Opportunities
5.4.1 High demand for tissue engineering in cosmetic and reconstructive surgery
5.4.2 Growing geriatric population presents a significant growth opportunity
6 Market Factor Analysis
6.1 Porters Five Forces Analysis
6.1.1 Bargaining Power of Suppliers
6.1.2 Bargaining Power of Buyers
6.1.3 Threat of New Entrants
6.1.4 Threat of Substitutes
6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
6.2.1 Primary activities
6.2.2 Secondary Activities
7 Immunosuppressant Drug Monitoring (ISD)
7.1 Overview
7.1 Diagnostic Tests for Transplantation
7.1.1 Therapeutic Drug Monitoring During Transplantation
7.2 Americas
7.2.1 North America
7.2.1.1 U.S.
7.2.1.2 Canada
7.2.2 South America
7.3 Europe
7.3.1 Germany
7.3.2 U.K
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 Rest of Asia Pacific
7.5 Middle East & Africa
7.5.1 Middle East
7.5.2 Africa
8 Global Transplant Diagnostics Market, By Products and Services
8.1 Introduction
8.1.1 Instruments
8.1.2 Reagents & Consumables
8.1.3 Software and Services
9 Global Transplant Diagnostics Market, By Screening Type
9.1 Introduction
9.1.1 Pre-Transplant Screening
9.1.2 Post-Transplant Screening
10 Global Transplant Diagnostics Market, By Organ Type
10.1 Introduction
10.1.1 Kidney
10.1.2 Liver
10.1.3 Heart
10.1.4 Lung
10.1.5 Pancreas
11 Global Transplant Diagnostics Market, By Application Type
11.1 Introduction
11.1.1 Research Applications
11.1.2 Diagnostic Applications
12 Global Transplant Diagnostics Market, By End User
12.1 Introduction
12.1.1 Commercial Service Providers
12.1.2 Hospitals and Transplant Centres
12.1.3 Research Laboratories and Academic Institutes
13 Global Transplant Diagnostics Market, By Region
13.1 Introduction
13.2 Americas
13.2.1 North America
13.2.1.1 U.S.
13.2.1.2 Canada
13.2.2 South America
13.3 Europe
13.3.1 Germany
13.3.2 U.K
13.3.3 France
13.3.4 Spain
13.3.5 Italy
13.3.6 Rest of Europe
13.4 Asia Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 Rest of Asia Pacific
13.5 Middle East & Africa
13.5.1 Middle East
13.5.2 Africa
14 Competitive Landscape
14.1 Company Market Share Analysis
14.1.1 Introduction
14.2 Competitive Landscape
14.2.1 Introduction
14.3 Key Developments
15 Company Profiles
15.1 Thermo Fisher Scientific Inc.
15.1.1 Company Overview
15.1.2 Financial Overview
15.1.3 Products Offering
15.1.4 Key Developments
15.1.5 SWOT Analysis
15.1.6 Key Strategy
15.2 Bio-Rad Laboratories, Inc.
15.2.1 Company Overview
15.2.2 Financial Overview
15.2.3 Products Offering
15.2.4 Key Developments
15.2.5 SWOT Analysis
15.2.6 Key Strategy
15.3 F. Hoffmann-La Roche AG
15.3.1 Company Overview
15.3.2 Financial Overview
15.3.3 Products Offering
15.3.4 Key Developments
15.3.5 SWOT Analysis
15.3.6 Key Strategy
15.4 Qiagen N.V.
15.4.1 Company Overview
15.4.2 Financial Overview
15.4.3 Products Offering
15.4.4 Key Developments
15.4.5 SWOT Analysis
15.4.6 Key strategy
15.5 BioM?rieux SA
15.5.1 Company Overview
15.5.2 Financial Overview
15.5.3 Products Offering
15.5.4 Key Developments
15.5.5 SWOT Analysis
15.5.6 Key Strategy
15.6 Illumina, Inc.
15.6.1 Company Overview
15.6.2 Financial Overview
15.6.3 Products Offering
15.6.4 Key Developments
15.6.5 SWOT Analysis
15.6.6 Key Strategy
15.7 Becton, Dickinson and Company
15.7.1 Company Overview
15.7.2 Financial Overview
15.7.3 Products Offering
15.7.4 Key Developments
15.7.5 SWOT Analysis
15.7.6 Key Strategy
15.8 Caredx, Inc.
15.8.1 Company Overview
15.8.2 Financial Overview
15.8.3 Products Offering
15.8.4 Key Developments
15.8.5 SWOT Analysis
15.8.6 Key Strategy
15.9 Gendx
15.9.1 Company Overview
15.9.2 Financial Overview
15.9.3 Products Offering
15.9.4 Key Developments
15.9.5 SWOT Analysis
15.9.6 Key Strategy
15.1 Zimmer Biomet
15.10.1 Company Overview
15.10.2 Financial Overview
15.10.3 Products Offering
15.10.4 Key Developments
15.10.5 SWOT Analysis
15.10.6 Key Strategy
15.11 Medtronic PLC
15.11.1 Company Overview
15.11.2 Financial Overview
15.11.3 Products Offering
15.11.4 Key Developments
15.11.5 SWOT Analysis
15.11.6 Key Strategy
15.12 DiaSorin S.P.A
15.12.1 Company Overview
15.12.2 Financial Overview
15.12.3 Products Offering
15.12.4 Key Developments
15.12.5 SWOT Analysis
15.12.6 Key Strategy
15.13 Merck KGaA
15.13.1 Company Overview
15.13.2 Financial Overview
15.13.3 Products Offering
15.13.4 Key Developments
15.13.5 SWOT Analysis
15.13.6 Key Strategy
15.14 Immucor, Inc.
15.14.1 Company Overview
15.14.2 Financial Overview:
15.14.3 Products Offering
15.14.4 Key Developments
15.14.5 SWOT Analysis
15.14.6 Key strategy
16 Appendix
16.1 Discussion Blue Print
16.2 Reference